ウェット型(新生血管型/滲出型)黄斑変性症(Wet (Neovascular / Exudative) Macular Degeneration):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2014
◆商品コード:GMDHC5792IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年11月30日
◆ページ数:225
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥624,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界におけるウェット型(新生血管型/滲出型)黄斑変性症(Wet (Neovascular / Exudative) Macular Degeneration)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・ウェット型(新生血管型/滲出型)黄斑変性症(Wet (Neovascular / Exudative) Macular Degeneration)の概要
・ウェット型(新生血管型/滲出型)黄斑変性症(Wet (Neovascular / Exudative) Macular Degeneration)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・ウェット型(新生血管型/滲出型)黄斑変性症(Wet (Neovascular / Exudative) Macular Degeneration)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・ウェット型(新生血管型/滲出型)黄斑変性症(Wet (Neovascular / Exudative) Macular Degeneration)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・ウェット型(新生血管型/滲出型)黄斑変性症(Wet (Neovascular / Exudative) Macular Degeneration)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Wet (Neovascular / Exudative) Macular Degeneration – Pipeline Review, H2 2014’, provides an overview of the Wet (Neovascular / Exudative) Macular Degeneration’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Wet (Neovascular / Exudative) Macular Degeneration
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Wet (Neovascular / Exudative) Macular Degeneration and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Wet (Neovascular / Exudative) Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Wet (Neovascular / Exudative) Macular Degeneration pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Wet (Neovascular / Exudative) Macular Degeneration Overview 9
Therapeutics Development 10
Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration – Overview 10
Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration – Comparative Analysis 11
Wet (Neovascular / Exudative) Macular Degeneration – Therapeutics under Development by Companies 12
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Wet (Neovascular / Exudative) Macular Degeneration – Products under Development by Companies 19
Wet (Neovascular / Exudative) Macular Degeneration – Companies Involved in Therapeutics Development 23
Alcon, Inc. 23
Allergan, Inc. 24
AlphaMab Co., Ltd 25
Amakem NV 26
Avalanche Biotechnologies, Inc. 27
Bayer AG 28
BIOCAD 29
Boehringer Ingelheim GmbH 30
Charlesson LLC. 31
Circadian Technologies Limited 32
Clearside BioMedical, Inc. 33
EyeCyte, Inc. 34
F. Hoffmann-La Roche Ltd. 35
Genzyme Corporation 36
GlaxoSmithKline plc 37
iCo Therapeutics Inc. 38
Icon Bioscience, Inc. 39
Iconic Therapeutics, Inc. 40
Intas Pharmaceuticals Ltd. 41
Kala Pharmaceuticals, Inc. 42
Lpath, Inc. 43
Mesoblast Limited 44
Neurotech Pharmaceuticals, Inc. 45
Novartis AG 46
Ohr Pharmaceutical Inc. 47
Ophthotech Corp. 48
Oxford BioMedica plc 49
PanOptica, Inc. 50
Pfenex Inc. 51
Pfizer Inc. 52
pSivida Corp. 53
Quark Pharmaceuticals, Inc. 54
Regeneron Pharmaceuticals, Inc. 55
ReGenX Biosciences, LLC 56
Resolvyx Pharmaceuticals, Inc 57
Santen Pharmaceutical Co., Ltd. 58
Sanwa Kagaku Kenkyusho Co., Ltd. 59
Tacere Therapeutics, Inc. 60
ThromboGenics NV 61
TRACON Pharmaceuticals, Inc. 62
Wet (Neovascular / Exudative) Macular Degeneration – Therapeutics Assessment 63
Assessment by Monotherapy Products 63
Assessment by Target 64
Assessment by Mechanism of Action 67
Assessment by Route of Administration 70
Assessment by Molecule Type 72
Drug Profiles 74
abicipar pegol – Drug Profile 74
aflibercept (recombinant) – Drug Profile 76
AGN-151200 – Drug Profile 79
ALG-1001 – Drug Profile 80
AMA-0428 – Drug Profile 82
ARC-1905 – Drug Profile 83
AVA-101 – Drug Profile 84
AVA-201 – Drug Profile 86
bertilimumab – Drug Profile 87
bevacizumab biosimilar – Drug Profile 89
BI-144807 – Drug Profile 90
C16Y Peptide – Drug Profile 91
CLT-005 – Drug Profile 92
conbercept – Drug Profile 93
DE-120 – Drug Profile 95
doxorubicin pegylated nanoparticle – Drug Profile 96
Drug for Wet Age Related Macular Degeneration – Drug Profile 97
EC-200 – Drug Profile 98
EC-400 – Drug Profile 99
ENV-705 – Drug Profile 100
fluocinolone acetonide – Drug Profile 101
GB-101 – Drug Profile 103
Gene Therapy for Wet Age-Related Macular Degeneration – Drug Profile 104
GZ-402663 – Drug Profile 105
hI-con1 – Drug Profile 106
LFG-316 – Drug Profile 107
Lpathomab – Drug Profile 109
LT-1009 – Drug Profile 110
MPC-MICRO-IO – Drug Profile 114
NM-9405 – Drug Profile 115
NT-503 – Drug Profile 116
NT-506 – Drug Profile 117
ocriplasmin (recombinant) – Drug Profile 118
OPT-302 – Drug Profile 121
PAN-90806 – Drug Profile 122
pazopanib hydrochloride – Drug Profile 124
pegpleranib sodium – Drug Profile 129
PF-05206388 – Drug Profile 131
PF-655 – Drug Profile 132
ranibizumab biosimilar – Drug Profile 134
ranibizumab biosimilar – Drug Profile 135
ranibizumab biosimilar – Drug Profile 136
REGN-2176-3 – Drug Profile 137
regorafenib – Drug Profile 138
RetinoStat – Drug Profile 141
RG-7716 – Drug Profile 142
RTH-258 – Drug Profile 143
RX-20001 – Drug Profile 145
SK-1011 – Drug Profile 146
Small Molecule to Inhibit Receptor Tyrosine Kinase for Wet Age-Related Macular Degeneration – Drug Profile 147
Small Molecules for Age Related Macular Degeneration – Drug Profile 148
Small Molecules to Inhibit VEGF and PDGF for Wet AMD – Drug Profile 149
Small Molecules to Inhibit VEGF for Wet AMD – Drug Profile 151
squalamine lactate – Drug Profile 153
TRC-105 – Drug Profile 156
triamcinolone acetonide – Drug Profile 158
TT-211 – Drug Profile 159
TT-231 – Drug Profile 160
X-82 – Drug Profile 161
XV-615 – Drug Profile 162
Wet (Neovascular / Exudative) Macular Degeneration – Recent Pipeline Updates 163
Wet (Neovascular / Exudative) Macular Degeneration – Dormant Projects 209
Wet (Neovascular / Exudative) Macular Degeneration – Discontinued Products 210
Wet (Neovascular / Exudative) Macular Degeneration – Product Development Milestones 211
Featured News & Press Releases 211
Appendix 220
Methodology 220
Coverage 220
Secondary Research 220
Primary Research 220
Expert Panel Validation 220
Contact Us 221
Disclaimer 221

[List of Tables]
Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration, H2 2014 14
Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration - Comparative Analysis, H2 2014 15
Number of Products under Development by Companies, H2 2014 17
Number of Products under Development by Companies, H2 2014 (Contd..1) 18
Number of Products under Development by Companies, H2 2014 (Contd..2) 19
Comparative Analysis by Late Stage Development, H2 2014 20
Comparative Analysis by Clinical Stage Development, H2 2014 21
Comparative Analysis by Early Stage Development, H2 2014 22
Products under Development by Companies, H2 2014 23
Products under Development by Companies, H2 2014 (Contd..1) 24
Products under Development by Companies, H2 2014 (Contd..2) 25
Products under Development by Companies, H2 2014 (Contd..3) 26
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Alcon, Inc., H2 2014 27
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Allergan, Inc., H2 2014 28
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by AlphaMab Co., Ltd, H2 2014 29
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Amakem NV, H2 2014 30
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Avalanche Biotechnologies, Inc., H2 2014 31
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Bayer AG, H2 2014 32
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by BIOCAD, H2 2014 33
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Boehringer Ingelheim GmbH, H2 2014 34
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Charlesson LLC., H2 2014 35
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Circadian Technologies Limited, H2 2014 36
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Clearside BioMedical, Inc., H2 2014 37
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by EyeCyte, Inc., H2 2014 38
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 39
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Genzyme Corporation, H2 2014 40
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by GlaxoSmithKline plc, H2 2014 41
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by iCo Therapeutics Inc., H2 2014 42
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Icon Bioscience, Inc., H2 2014 43
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Iconic Therapeutics, Inc., H2 2014 44
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Intas Pharmaceuticals Ltd., H2 2014 45
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Kala Pharmaceuticals, Inc., H2 2014 46
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Lpath, Inc., H2 2014 47
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Mesoblast Limited, H2 2014 48
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Neurotech Pharmaceuticals, Inc., H2 2014 49
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Novartis AG, H2 2014 50
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Ohr Pharmaceutical Inc., H2 2014 51
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Ophthotech Corp., H2 2014 52
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Oxford BioMedica plc, H2 2014 53
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by PanOptica, Inc., H2 2014 54
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Pfenex Inc., H2 2014 55
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Pfizer Inc., H2 2014 56
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by pSivida Corp., H2 2014 57
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Quark Pharmaceuticals, Inc., H2 2014 58
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2014 59
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by ReGenX Biosciences, LLC, H2 2014 60
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Resolvyx Pharmaceuticals, Inc, H2 2014 61
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2014 62
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H2 2014 63
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Tacere Therapeutics, Inc., H2 2014 64
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by ThromboGenics NV, H2 2014 65
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by TRACON Pharmaceuticals, Inc., H2 2014 66
Assessment by Monotherapy Products, H2 2014 67
Number of Products by Stage and Target, H2 2014 69
Number of Products by Stage and Mechanism of Action, H2 2014 72
Number of Products by Stage and Route of Administration, H2 2014 75
Number of Products by Stage and Molecule Type, H2 2014 77
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics - Recent Pipeline Updates, H2 2014 167
Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects, H2 2014 213
Wet (Neovascular / Exudative) Macular Degeneration - Discontinued Products, H2 2014 214

[List of Figures]
Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration, H2 2014 14
Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration - Comparative Analysis, H2 2014 15
Number of Products under Development by Companies, H2 2014 16
Comparative Analysis by Clinical Stage Development, H2 2014 21
Comparative Analysis by Early Stage Products, H2 2014 22
Assessment by Monotherapy Products, H2 2014 67
Number of Products by Top 10 Targets, H2 2014 68
Number of Products by Stage and Top 10 Targets, H2 2014 68
Number of Products by Top 10 Mechanism of Actions, H2 2014 71
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 71
Number of Products by Top 10 Routes of Administration, H2 2014 74
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 75
Number of Products by Top 10 Molecule Types, H2 2014 76
Number of Products by Stage and Top 10 Molecule Types, H2 2014 77

【掲載企業】

Alcon, Inc.
Allergan, Inc.
AlphaMab Co., Ltd
Amakem NV
Avalanche Biotechnologies, Inc.
Bayer AG
BIOCAD
Boehringer Ingelheim GmbH
Charlesson LLC.
Circadian Technologies Limited
Clearside BioMedical, Inc.
EyeCyte, Inc.
F. Hoffmann-La Roche Ltd.
Genzyme Corporation
GlaxoSmithKline plc
iCo Therapeutics Inc.
Icon Bioscience, Inc.
Iconic Therapeutics, Inc.
Intas Pharmaceuticals Ltd.
Kala Pharmaceuticals, Inc.
Lpath, Inc.
Mesoblast Limited
Neurotech Pharmaceuticals, Inc.
Novartis AG
Ohr Pharmaceutical Inc.
Ophthotech Corp.
Oxford BioMedica plc
PanOptica, Inc.
Pfenex Inc.
Pfizer Inc.
pSivida Corp.
Quark Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
ReGenX Biosciences, LLC
Resolvyx Pharmaceuticals, Inc
Santen Pharmaceutical Co., Ltd.
Sanwa Kagaku Kenkyusho Co., Ltd.
Tacere Therapeutics, Inc.
ThromboGenics NV
TRACON Pharmaceuticals, Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[ウェット型(新生血管型/滲出型)黄斑変性症(Wet (Neovascular / Exudative) Macular Degeneration):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆